The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
FDA-ordered report tackles how to manage cybersecurity risks of legacy devices
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: A report commissioned by the